Santhera closes exclusive license agreement with Catalyst Pharmaceuticals for Vamorolone

Betsy Goodfellow | July 19, 2023 | News story | Medical Communications License Agreement, Musculo-skeletal disorder, Vamorolone, catalyst, santhera 

Santhera Pharmaceuticals has announced the closing of its exclusive North American license agreement for vamorolone with Catalyst Pharmaceuticals. The agreement was initially announced on the 20 June, 2023.

Under the terms of the agreement, Catalyst has commercialisation rights in North America for vamorolone for the treatment of Duchenne muscular dystrophy (DMD) and all potential future indications for a total consideration of up to $231m plus royalties from product sales to be paid to Santhera.

Upon closing of this agreement, Santhera will receive an upfront payment of $75m, and an additional $15m through the sale of treasury shares to Catalyst. The company is also expected to receive further milestone payments dependent on the achievement of certain criteria such as approval from the US Food and Drug Administration (FDA).

Dario Eklund, Santhera’s CEO, commented: “The partnership with Catalyst allows us to execute our European strategy for vamorolone, supported by adequate funding, and provides financial security for the Company’s operations into 2025. It also, subject to regulatory approval, opens up the possibility of expanding vamorolone’s potential by jointly addressing additional indications beyond DMD. With partners in North America and China, it enables us to fully focus on bringing vamorolone to DMD patients in Europe, and we are preparing for a first launch in Germany which could occur as early as in late 2023, subject to approval. For markets outside the five largest European countries plus Benelux, where we will commercialise vamorolone ourselves, we continue to evaluate additional partnerships.”

Betsy Goodfellow

Related Content

Sun Pharma and Pharmazz enter license agreement for Tyvalzi in India

Sun Pharma has announced that one of its wholly owned subsidiaries has entered into a …

Ionis and Novartis partner for CVD treatment programme

Ionis Pharmaceuticals has announced that it has entered into a new collaboration and license agreement …

Nanobiotix announces license agreement with Janssen for development and commercialisation of new cancer treatment

Nanobiotix has announced a global licensing, co-development and commercialisation agreement with Janssen Pharmaceutica NV, one …

Latest content